Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

koto_feja I covered Nurix Therapeutics, Inc. (NASDAQ:NRIX) over a year ago, and in this article, besides giving an update, I'm also going to take a look at the science behind small molecule BTK degradation and emerging competition in the field. About Nurix Nurix has been around for 15 years, but IPO-ed just four years ago. I covered it from the beginning, and in that time, the stock and the market cap have seen multifold increases. The current market cap is a decent $1.6bn, despite the latest programs being ...